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ABSTRACT: The identification of more reliable diagnostic or prognostic biomarkers in age-related 
neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), is urgently needed. The objective in 
this study was to identify more reliable prognostic biomarkers of ALS mirroring neurodegeneration that could 
be of help in clinical trials. A total of 268 participants from three cohorts were included in this study. The muscle 
and blood cohorts were analyzed in two cross-sectional studies, while the serial blood cohort was analyzed in a 
longitudinal study at 6-monthly intervals. Fifteen target genes and fourteen proteins involved in muscle 
physiology and differentiation, metabolic processes and neuromuscular junction dismantlement were studied in 
the three cohorts. In the muscle biopsy cohort, the risk for a higher mortality in an ALS patient that showed high 
Collagen type XIX, alpha 1 (COL19A1) protein levels and a fast progression of the disease was 70.5% (P < 0.05), 
while in the blood cohort, this risk was 20% (P < 0.01). In the serial blood cohort, the linear mixed model analysis 
showed a significant association between increasing COL19A1 gene levels along disease progression and a faster 
progression during the follow-up period of 24 months (P < 0.05). Additionally, higher COL19A1 levels and a faster 
progression increased 17.9% the mortality risk (P < 0.01). We provide new evidence that COL19A1 can be 
considered a prognostic biomarker that could help the selection of homogeneous groups of patients for upcoming 
clinical trial and may be pointed out as a promising therapeutic target in ALS. 
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Amyotrophic Lateral Sclerosis (ALS) is a devastating 
neurodegenerative disease that promotes a progressive 
motor neuron loss and muscle weakness. The survival 
period of time is within 2 to 10 years after the signs and 
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symptoms firstly appear [1,2]. A large proportion of 
people with ALS are sporadic cases and they lack of clear 
genetic association, while a small proportion of ALS 
patients, 5-10%, correspond to familial ALS cases and 
they have a family history of ALS or a related condition 
called frontotemporal dementia (FTD). FTD is a 
progressive brain disorder that affects personality, 
behavior, and language and this disorder is present in 20% 
of the ALS patients [1]. The most known mutations that 
produce the typical adult-onset ALS phenotype in the 
familial cases are related to the copper/zinc superoxide-
dismutase-1 gene (SOD1), Tar DNA-binding protein gene 
(TARDBP) (previously known as TDP-43), DNA/RNA-
binding protein called FUS (fused in sarcoma), TLS 
(translocation in liposarcoma), and the most recent 
hexanucleotide repeat expansion in C9ORF72 [1,3]. 
The complexity in the discovery of potential 
biomarkers for neurodegenerative diseases, especially in 
the case of ALS, relies greatly upon the lack of 
etiopathogenic origin in the whole population of ALS 
patients. In fact, ALS shares physiophatological 
abnormalities with other neuropathies such as 
Alzheimer’s disease or Parkinson’s disease and, more 
precisely, this close connection among these 
neurodegenerative diseases makes the identification of 
specific biomarkers for ALS a difficult task [4,5]. 
Dementia is also relatively frequent in ALS and may be a 
consequence of either frontotemporal lobar degeneration 
(FTLD) or a result of co-existing Alzheimer disease [6,7]. 
In this complex scenario and in spite of the numerous 
studies attempting to find specific gene/protein targets 
exclusive for ALS and characteristic of both familial and 
sporadic cases, the prognosis of the disease remains poor. 
Another main challenge relies on the fact that ALS is a 
multifactorial and relentlessly progressive disease, which 
hinders the use of an effective treatment. Therefore, the 
search for reliable biomarkers of the disease that can 
provide the identification of accurate indicators of early 
symptoms, disease progression, or even patients’ survival, 
is urgently needed. It has been reported that older age at 
symptom onset, early respiratory muscle dysfunction, and 
bulbar-onset disease are associated with reduced survival, 
whereas limb-onset disease, younger age at presentation, 
and longer diagnostic delay are independent predictors of 
prolonged survival [8]. In this study, our main objective 
was to identify molecular biomarkers mirroring 
neurodegeneration in ALS patients that can also enable an 
earlier prognosis in the disease.  
Previous studies by our research workgroup on 
transgenic SOD1G93A mice suggested five genes, Mef2c 
(myocyte enhancer factor 2C), Gsr (oxidative stress 
metabolism), Col19a1 (collagen, type XIX, alpha 1), 
Calm1 (calmodulin 1), and Snx10 (sorting nexin 10), as 
potential genetic biomarkers of longevity in transgenic 
SOD1G93A mice, one of the best-characterized animal 
models for ALS that resembles both clinical and 
pathological characteristics of ALS patients [9,10]. 
Consequently, our next and main challenge was to analyze 
in depth the prognostic nature of the biomarkers identified 
in this animal model in ALS patients to correlate these 
biomarkers to the clinical variables routinely monitored in 
ALS patients to improve accuracy in the prediction. Mef2c 
gene is involved in muscle differentiation and 
regeneration [11], Gsr and Calm1 genes are involved in 
oxidative stress [12] and calcium homeostasis [13], 
respectively, Col19a1 gene is involved in the maintenance 
of muscle integrity [14] and Snx10 gene can play a 
relevant role in the muscle and bone dysregulation [15]. 
To achieve this challenge, we firstly aimed to test a panel 
of biomarkers in muscle biopsies from ALS patients and 
secondly, in blood samples to identify broadly applicable 
prognostic biomarkers for ALS disease progression in a 
non-invasive way. More in depth, the specific objective in 
this study was to look at the associations among molecular 
markers and clinical variables to identify more reliable 
prognostic biomarkers that could be of help in clinical 
trials. The findings in this study revealed that COL19A1 
levels in muscle biopsies and blood samples from ALS 
patients can be considered a prognostic biomarker to 
accurately monitor the disease progression, especially in 
those patients that share a high disability in the first 
symptomatic stages of the disease. 
 
MATERIALS AND METHODS 
 
Study approval 
 
Blood and muscle biopsy samples from patients were 
obtained with written informed consent prior to inclusion 
in the study to publication of their case details, which has 
been conducted according to Declaration of Helsinki 
principles, following the ethical rule of the October 12th 
Hospital (local Ethical Committee of Clinical 
Investigation approval reference 14/2007, Madrid, Spain), 
and according to the Directive 2004/23/EC of the 
European Parliament and of the Council. Participants 
were identified by number, not by name. 
 
Experimental Design 
 
This study included a total of 268 participants from three 
cohorts, matched for age and gender, whenever possible. 
For the muscle biopsy cohort, a total of 49 ALS patients, 
24 healthy controls and 14 patients with other 
neuropathies (ONP) were included (Table 1). In the blood 
cohort, 59 ALS patients, 58 healthy controls and 24 ONP 
patients were included (Table 2). A second subgroup of 
forty sporadic ALS patients was monitored in the serial 
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blood cohort at 6-monthly intervals during a follow-up 
period of 24 months from the symptom onset in each 
patient (Table 3). The muscle and blood cohorts were 
analyzed in two cross-sectional studies, while the serial 
blood cohort was analyzed in a longitudinal study. The 
participants were different in the three cohorts (Fig. 1). 
 
 
Table 1. General and clinical characteristics of the study subjects in the muscle biopsy study cohort. 
 
 
Type of cohort (N)  Muscle biopsy cohort* (N = 87) 
   ALS patients ONP patients Healthy controls 
Patients' characteristics   (n =49) (n = 14) (n = 24) 
Gender (n) Female 15 8 19 
 Male 34 6 5 
Age at illness onset (mean ± SD)  57.02 ± 12.42 43.79 ± 16.02  
Age at biopsy (mean ± SD)  58.65 ± 12.52 42.34 ± 25.89 55.07 ± 26.07 
Disease duration, months (mean ± SD)  19.54 ± 25.15   
Clinical Phenotype (n) ALS, spinal 42   
 ALS, bulbar 6   
 ALS + FTD 1   
 OMD  5  
 SMA  5  
 CIDP  1  
 KD  1  
 NMD  1  
 AD (Early)  1  
ALSFRS-r at biopsy (mean ± SD)  40.24 ± 6.20   
El Escorial criteria at onset (n) Unavailable 33   
 Defined 1   
 Probable 6   
 Possible 5   
 Suspected 4   
Genetic Diagnosis (n) SALS 26   
 FALS 6   
 SALS + FTD 2   
 MND-FTD 1   
 PLS-SALS 1   
 PMA-SALS 1   
  Unavailable 12   
* All subjects were of caucasian ethic group.    
ALS, amyotrophic lateral sclerosis; SALS, sporadic ALS; FALS, familial ALS; ALSFRS-r, the revised ALS Functional Rating Scale; ONP, other 
neuropathies; FTD, frontal temporal dementia; OPMD, oculopharyngeal muscular dystrophy; SMA, spinal muscular atrophy; CIDP, chronic 
inflammatory demyelinating polyneuropathy; KD, Kennedy Disease; MND, motor neuron disease (cervical myelopathy); AD, Alzheimer Disease (early); 
PLS, Primary Lateral Sclerosis; PMA, Primary Muscular Atrophy. 
The clinical characteristics of the participants in each 
cohort were firstly assessed. In the ALS group, these 
characteristics included the revised ALS Functional 
Rating Scale-revised (ALSFRS-r), the ALSFRS-r slope 
(48-ALSFRS-r /disease duration at time assessment), the 
clinical phenotype, the diagnostic delay, the age at onset, 
age at sampling, gender, the revised El Escorial criteria 
[16], the onset site and the genetic diagnosis. The 
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ALSFRS-r provided an estimation of the patient’s degree 
of functional impairment. In the serial blood cohort, 
ALSFRS-r was evaluated serially at 6-monthly intervals 
to objectively assess any progression of the disease at each 
sample extraction time. Additionally, the ALSFRS-r slope 
was calculated in both cross-sectional and longitudinal 
studies to monitor the rate of progression based on the 
functional scale of the patient. The classification system 
to estimate the ALSFRS-r slope was based on the previous 
system used by Elamin and coworkers [17]. The 
interpretation of this classification system is as follows: 
ALSFRS-R slope <0.025 points/month, 0.25–0.49 
points/month, 0.50–0.99 points/month, and ≥1 
points/month. This means the higher ALSFRS-r slope (≥1 
points/month), the faster functional decline. 
 
 
Table 2. General and clinical characteristics of the study subjects in the blood study cohort. 
 
 
Type of cohort (N)                              Blood cohort* (N = 141) 
  ALS patients ONP patients Healthy controls 
Patients’ characteristics  (n = 59) (n= 24) (n = 58) 
Gender (n) Female 25 10 31 
 Male 34 14 27 
Age at illness onset (mean ± SD)  60.98 ± 14.07 43.79 ± 16.02  
Age at biopsy (mean ± SD)  62.10 ± 14.00 55.74 ± 12.32 55.74 ± 12.31 
Disease duration, months (mean ± SD)  14.53 ± 14.66   
Clinical Phenotype (n) ALS 59   
 CIDP  1  
 KD  1  
 NMD  1  
 AD (Early)  1  
 BMD  2  
 ES  1  
 FMD  4  
 HPP (Type-1)  1  
 LMD  1  
 MM  1  
 MD (Type-1)  9  
 MD (Type-2)  1  
Site at onset (n) Lower limb 27   
 Upper limb 17   
 Bulbar 10   
 Generalized 4   
 Respiratory 1   
 None    
ALSFRS-r at onset (mean ± SD)  42.71 ± 6.86   
ALSFRS-r at biopsy (mean ± SD)  34.47 ± 7.82   
El Escorial criteria at onset (n) Unavailable 18   
 Defined 17   
 Probable 18   
 Possible 3   
 Suspected 2   
Genetic Diagnosis (n) SALS 33   
 FALS (4m**) 18   
 FALS (SOD1) 6   
 FALS (SETX) 1   
 Unavailable 1   
*All subjects were of caucasian ethic group except two latin-american and one asiatic. ** Four mutations for ALS are present: 
SOD1/TDP43/FUS/c9orf72. ALS, amyotrophic lateral sclerosis; ONP, other neuropathies; CIDP, chronic inflammatory demyelinating 
polyneuropathy; KD, Kennedy Disease; MND, motor neuron disease (cervical myelopathy); AD, Alzheimer Disease (early); BMD, Becker's 
Muscular Dystrophy; ES, extrapyramidal syndrome; FMD, Facio-capulo-humeral muscular distrophy; HPP, Hypokaliemic Periodic Paralysis; 
LMD, limb-girdle muscular distrophy; MM, mild myotonia; MD, Myotonic Dystrophy. 
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Figure 1. Flow diagram of the three study cohorts and overview of the study design. A total of 148 ALS patients were 
enrolled in two cross-sectional studies and one longitudinal study to detect associations among molecular markers and 
clinical variables in skeletal muscle biopsy (ALS muscle biopsy cohort) and blood samples (ALS blood cohort) and to 
identify prognostic biomarkers along the disease progression, especially in serial blood samples. 
 
RNA extraction and purification from muscle biopsies 
and blood samples 
 
Muscle biopsy samples were mainly obtained from 
brachial biceps using open biopsy after subcutaneous 
anesthesia administration and the samples were 
immediately frozen in liquid nitrogen. The biopsy sample 
from each individual was used to obtain RNA and protein 
extracts, using used the same methodology as the one 
employed in a previous study [18]. 
Blood samples were immediately processed and 
treated with a Ficoll gradient (Ficoll-PaqueTM Plus; GE 
Healthcare, Madrid, Spain). RNA extraction and 
purification were carried out following the manufacturer’s 
instructions. In the case of blood samples received frozen 
in Pax tubes, the PAXgene Blood RNA Kit (PreAnalytiX, 
8634 Hombrechtikon, Switzerland) was used to extract 
the RNA fraction. In all the muscle and blood samples, the 
cDNA was also obtained from 1 g of total extracted 
RNA (High Capacity cDNA RT kit; Applied Biosystems, 
Madrid, Spain). One muscle biopsy sample and one blood 
sample were obtained per participant from the muscle 
biopsy and blood cohorts, respectively. In the serial blood 
cohort, serial blood samples obtained every six months. In 
this case, a maximum of five serial samples were collected 
per patient, starting at the first age of sampling. 
 
Gene expression analysis 
 
The gene expression analysis was performed by real-time 
PCR (7500 Real-Time PCR System, Applied Biosystem, 
Madrid, Spain). Fifteen target genes were included in this 
analysis (Table 4). The Taqman probes (Applied 
Biosystems, Madrid, Spain) (Table 4) used in this study 
were tested and in all the cases the efficiency was near 
100%. All the real-time PCR reactions were done in 
triplicate and three endogenous genes (glyceraldehyde 3-
phosphate dehydrogenase, GAPDH, hypoxanthine 
phosphoribosyltransferase, HPRT, and TATA-binding 
protein, TBP) were used to normalize the target gene 
expression. Data was quantitatively analyzed with respect 
to a calibrator sample, selected from a control subject, 
using the Ct method.  
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Table 3. General and clinical characteristics of sporadic ALS patients in the serial blood study cohort. 
 
 
Type of cohort (N)  Serial blood cohort * (N = 40) 
  ALS patients (n =40) 
Patients' characteristics  Onset 6 months 12 months 18 months 24 months 
Gender (n) Female 15   
 Male 25   
Age at illness onset (mean ± SD)  57.02 ± 12.42   
Disease duration, months (mean ± 
SD) 
 57.53 ± 23.48   
Clinical Phenotype (n) 
SALS, UMN and 
LMN spinal 
25   
 SALS, UMN spinal 1   
 SALS, LMN spinal 14   
ALSFRS-r (mean ± SD)  27.8 ± 5.47 23.8 ± 5.94 19.6 ± 6.27 18.5 ± 6.76 17.6 ± 6.76 
El Escorial criteria at onset (n) Defined 25   
 Possible 4     
 Probable 11     
Forced vital capacity (FVC) (%)  10.4 ± 6.11 14.6 ± 6.99 15.0 ± 10.44 17.8 ± 11.12 20.6 ± 15.74 
Body mass index (BMI) (Kg/m2)  26.5 ± 3.81 26.3 ± 3.82 25.9 ± 4.11 26.0 ± 3.71 25.3 ± 3.55 
Genetic Diagnosis (n) SALS 40   
*All subjects were of caucasian ethic group. SALS, sporadic ALS; UMN, upper motor neuron; LMN, lower motor neuron; FVC, forced vital 
capacity; BMI, body mass index. 
 
Protein expression analysis 
 
Fourteen target proteins were included in this analysis 
(Table 5). We used the same methodology as the one 
employed in a previous study [18]. In this study, the 
protein extracts were subjected to 10% SDS-
polyacrylamide gel electrophoresis. The corresponding 
primary antibody was diluted 1:500 in blocking buffer and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 
Santa Cruz Biotechnology, Quimigen S.L., Madrid, 
Spain) was used as housekeeping protein to normalize 
protein levels in target proteins. The integrated optical 
density (IOD) values of the target proteins were 
accurately normalized with respect to the housekeeping 
protein IOD values. 
 
 
Table 4. Taqman® probe and primer mixtures used in gene expression assays. 
 
Gene name Gene Symbol Assay ID 
Ankyrin repeat domain 1 (cardiac muscle) ANKRD1 Hs00173317_m1 
Collagen, type XIX, alpha 1 COL19A1 Hs00156940_m1 
F-box protein 32 FBXO32 Hs01041408_m1 
Glycogen synthase kinase 3  GSK3 Hs01047719_m1 
Glutathione reductase GSR Hs00167317_m1 
Inositol(myo)-1(or 4)-monophosphatase 1 IMPA1 Hs04188597_m1 
Myocyte enhancer factor 2C MEF2C Hs00231149_m1 
Myogenin (myogenic factor 4) MYOG Hs01072232_m1 
Reticulon 4 RTN4 (NOGO A) Hs00199671_m1 
Ras-related associated with diabetes RRAD Hs00188163_m1 
Senataxin SETX Hs00209294_m1 
Sarcolipin SLN Hs01888464_s1 
Sorting nexin 10 SNX10 Hs00203362_m1 
Superoxide dismutase 1, soluble SOD1 Hs00533490_m1 
Vacuolar protein sorting 54 homolog (S. cerevisiae) VPS54 Hs00212957_m1 
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Table 5. Primary antibodies used in protein expression assays. 
 
Protein name Protein Symbol Reference number, primary antibodies 
Anti-Apoptosis-inducing factor, mitochondrion-associated, 1 AIFM1 SAB2100079, anti-rabbit, Sigma-Aldrich 
Ankyrin repeat domain 1 (cardiac muscle) ANKRD1 SAB1101413, anti-rabbit antibody, Sigma-Aldrich 
Aspartate transcarbamylase CAD SAB2100334, anti-rabbit, Sigma-Aldrich 
Collagen, type XIX, alpha 1 COL19A1 H00001310-A01, anti-mouse, Novus Biologicals 
Coenzyme Q3 homolog CoQ3 WH0051805M1, anti-mouse, Sigma-Aldrich 
F-box protein 32 FBXO32 ab67866, anti-mouse, ABCAM 
Glutathione reductase GSR WH0002936M1, anti-mouse, Sigma-Aldrich 
Inositol(myo)-1(or 4)-monophosphatase 1 IMPA1 SAB2103588, anti-rabbit, Sigma-Aldrich 
Myogenin (myogenic factor 4) MYOG WH0004656M1, anti-mouse, Sigma-Aldrich 
Anti-CoQ1 PDSS1 AV46195, anti-rabbit, Sigma-Aldrich 
Reticulon 4 RTN4 (NOGO A) R3282, anti-rabbit, Sigma-Aldrich 
Sarcolipin SLN ab25860, anti-rabbit, ABCAMK 
Sorting nexin 10 SNX10 WH0029887M1, anti-mouse, Sigma-Aldrich 
Vacuolar protein sorting 54 homolog (S. cerevisiae) VPS54 SAB1401701, anti-mouse, Sigma-Aldrich 
 
Statistical analysis 
 
The normality of data was verified by means of the 
Kolmogorov-Smirnov test. The data that did not show a 
homogeneous distribution was analyzed using Kruskal-
Wallis tests to compare means, while the homogeneous 
distribution of the data was studied using Student's-t test. 
All values were expressed as the mean ± standard error of 
the mean (SEM). The area under ROC curves (AUC) was 
calculated, following the same methodology used in a 
previous study to explore the support for diagnosis nature 
of the molecular markers under study [19]. Binary and 
multinomial logistic regression analysis was used to 
investigate the influence of molecular markers on the 
clinical variables. All the clinical variables were 
converted to categorical variables in the whole regression 
analysis. Cox proportional hazards regression analysis 
was undertaken in case of continuous variables, such as 
COL19A1 levels, to evaluate their prognostic nature. 
Patients who were alive at the time of analysis were 
censored. After identifying significant predictors of 
prognosis on multivariate analysis, internal validation of 
the model was carried out using boot-strapping techniques 
using 1000 random samples to obtain 95 % confidence. 
Leave-one-out cross validation was used to confirm the 
accuracy in each regression analysis. Linear mixed-
effects models were used to estimate the influence of 
COL19A1 levels on outcomes in the longitudinal study. 
The fixed effect of the baseline value of the outcome and 
the period of time in months on outcomes was modeled. 
Random intercepts were used to model between-patients 
variability. Statistical analysis was performed using SPSS 
Statistics version 22 (IBM, Spain). A two-sided 
significance level of 5% was considered statistically 
significant. 
RESULTS 
 
COL19A1 levels were strongest predictors of survival in 
the muscle biopsy cohort  
 
The expression profile of fifteen genes and fourteen 
proteins was analyzed in the muscle biopsy cohort and 
compared to healthy subjects and to ONP groups. Only 
COL19A1 gene and protein levels were significantly 
different in the ALS patient group with respect to healthy 
controls and the ONP groups. Remarkably, COL19A1 
protein levels were approximately five-fold increase in the 
ALS patient group respect to healthy controls and the 
ONP groups in, while COL19A1 gene levels were 
approximately thirty–fold increase in ALS patients 
respect to the control groups (Fig. 2A). Furthermore, 
comparison of COL19A1 expression profile with the Area 
under ROC curves (AUC) was performed to test if 
COL19A1 levels could have a good performance as 
support for diagnosis tool. In order to assess predictive 
values, selected cut-off values were set for COL19A1 gene 
(COL19A1 gene >7), and for COL19A1 protein 
(COL19A1 protein >1) to minimize false positive cases 
(Fig. 2B). The parallel combination of data improved 
performance related to predictive values, yielding a 71.0% 
sensitivity and 100% specificity with a positive predictive 
value (PPV) of 99.9% and a negative predictive value 
(NPV) of 99.9% (likelihood ratio, LR: 6.00, confidence 
interval, CI: 2.471-14.571). 
We next explored the prognostic nature of COL19A1 
gene in relation to the clinical parameters measured in 
ALS patients. The ALSFRS-r score provides an 
estimation of the patient’s degree of functional 
impairment. Since the 1990s, this functional rating scale 
has been developed to measure the disease progression in 
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the patients from time at onset to time at diagnosis and 
follow-up visits in the clinic. This scale is based on a set 
of twelve questions graded on a scale of 0 to 4. The 
responses obtained in this questionnaire can shed light on 
the different domains that might be affected by the 
disease. The new and revised scale considers 48 points as 
the maximum score for each question [20]. It has been 
described that the rate of deterioration in the patient 
correlates with survival and, at the same time, it also 
correlates with a lower score in the ALSFRS-r scale, 
suggesting approximately an average loss of a point per 
month along the disease progression and therefore a 
higher disability in the patient [20]. Spearman correlation 
between ALSFRS-r score at sampling and COL19A1 gene 
levels was found significant (r= -0.349, P=0.025), which 
suggested that high COL19A1 levels could be related to 
lower ALSFRS-r scores at sampling and a higher 
disability in the patient. Binary logistic regression 
analysis showed that ALS patients that exhibited 
ALSFRS-r scores at sampling higher or equal than 40, 
also showed a probability of expressing lower COL19A1 
gene and protein levels than ALS patients with ALSFRS-
r scores at sampling lower than 40 (COL19A1 gene levels: 
odds ratio (OR): 0.839, 95% confidence of interval (CI): 
0.714-0.987, P=0.034; COL19A1 protein levels: OR: 
0.977, CI: 0.877-1.089, P=0.674). In addition, Spearman 
correlation between disease duration and diagnostic delay 
(time from symptom onset to diagnosis) was found 
significant (r= 0.579, P<0.0001) as well as between 
disease duration and ALSFRS-r slope at sampling (r= -
0.761, P<0.0001) and between diagnostic delay and 
ALSFRS-r slope at sampling (r= -0.556, P<0.0001). In 
this sense, ALS patients that showed a longer diagnostic 
delay (more than one year) also showed longer disease 
duration and a slow progression of the disease (lower 
ALSFRS-r slope scores, lower than 1 points/month).  
 
 
 
 
Figure 2. Relative gene and protein expression levels of COL19A1 in the muscle biopsy study cohort. Gene and protein 
expression levels of COL19A1 in healthy subjects, ALS patients and other neuropathies patients (A). Kruskal Wallis tests showed 
significant differences among ALS patients and the other two groups under study, when gene and protein expression levels were 
tested (P < 0.001, **). (B) Areas under ROC curves (AUC) of gene and protein expression of COL19A1 were calculated to test 
its support for diagnosis criterion in ALS patients (P <0.001, **). A total of 49 ALS (FALS and SALS) participants were included 
in this study and matched with 24 control individuals, and 14 ONP; SE: standard error. 
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Figure 3. Relative gene expression analysis in the blood study cohort. Transcriptional expression levels of MEF2C, 
NOGO A, SOD1, COL19A1 and SNX10 in healthy subjects, ALS patients and other neuropathies patients. (A) Kruskal 
Wallis tests showed significant differences among ALS patients and healthy participants in all the cases except for SNX10. 
Significant differences among other neuropathies patient group and ALS patient group were found in all the cases except 
for NOGO A and SOD1. (B) Area under ROC curves of COL19A1 and the ratios COL19A1/NOGO A and SOD1/NOGO A 
were calculated in the sporadic ALS patient group. Significant differences were found between COL19A1 and the ratio 
COL19A1/NOGO A, and between COL19A1 and the ratio SOD1/NOGO A. A total of 141 participants were included in this 
study: 58 control individuals, 24 other neuropathology’s individuals and 59 ALS patients (FALS and SALS patients); (*P 
< 0.05; ** P < 0.001), SE: standard error. 
 
The next step was to investigate the role of COL19A1 
levels in the disease progression, the diagnostic delay and 
the ALSFRS-r slope at sampling. Linear regression 
analysis suggested the disease duration correlated 
positively with the diagnostic delay (B coefficient: 0.820, 
CI: 0.452-1.189, P=0.008) and negatively with the 
ALSFRS-r slope (B coefficient: -10.587, CI: -19.586-(-
1.588), P=0.023) and with low COL19A1 protein levels 
(B coefficient: -14.407, CI: -30.228-1.414, P=0.043), 
suggesting the higher ALSFRS-r slope scores (faster 
progression of the disease) and the higher COL19A1 
protein levels, the shorter disease duration. Additionally, 
the diagnostic delay correlated positively with the disease 
duration in ALS patients that exhibited low COL19A1 
gene levels (B coefficient: 0.909, CI: 0.556-1.263, 
P<0.0001), suggesting that low COL19A1 gene levels 
were closely associated with ALS patients that showed a 
longer disease duration and therefore, a diagnostic delay 
higher than one year. 
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Finally, to validate the prognostic nature of 
COL19A1 expression levels multivariable Cox 
proportional hazards regression model was performed 
using leave-one-out cross validation. This analysis 
suggested that the lifespan in ALS patients showing 
COL19A1 protein levels above mean average (1.06) and 
additionally a fast progression of the disease (ALSFRS-r 
slope scores at sampling  1 points/month) could be 
reduced 70.5% (ALSFRS-r slope, hazard ratio, HR: 
1.569, CI: 1.245-1.976, P=0.000; COL19A1 protein 
levels, HR: 2.158, CI: 1.020-4.566, P=0.044), 
emphasizing the significance of COL19A1 levels as a 
useful, feasible, and potentially prognostic factor in 
patients with ALS. Since COL19A1 levels were found 
strongest predictors of survival in the ALS muscle biopsy 
cohort, we next investigated a second cohort of patients, 
the blood cohort, to validate these findings. 
 
 
 
Figure 4. Linear mixed model analysis in the serial blood study cohort. (A) Linear mixed model analysis showed a 
significant relationship among a faster disease progression and high COL19A1 levels from symptom onset, each dashed line 
corresponds to the COL19A1 levels from each patient. (B) Mean change from baseline in the ALSFRS-r score in patients that 
were monitored at 6-monthly intervals during a follow-up period of 24 months from the symptom onset that show COL19A1 
levels above (green dot and line) and below (blue dot and line) average at first evaluation. Student's-t test was performed to 
analyze statistical differences between groups (P < 0.001). A total of 40 SALS patients from the serial blood study cohort 
were included. 
 
The prognostic nature of COL19A1 levels was also 
validated in blood samples from ALS patients 
 
The gene expression profile of fifteen genes was analyzed 
in the ALS blood cohort and compared to the healthy 
group of subjects and ONP patients. Results showed that 
only COL19A1 and MEF2C levels were significantly 
deregulated in the ALS patient group compared to healthy 
controls and the ONP groups (Fig. 3A). Albeit COL19A1 
levels were found significantly higher in the ALS patient 
group respect to the healthy and ONP groups, this 
difference in the gene expression levels was not so 
remarkable than the difference observed in the muscle 
biopsy cohort (approximately 1.75-fold change respect to 
the healthy control group and 2.35-fold change respect to 
the ONP group), which is in accordance with the fact that 
COL19A1 gene is mostly expressed and related to the 
skeletal muscle tissue, rather than blood tissue. ROC 
curves analysis showed that the sensitivity and specificity 
ratios between COL19A1 and COL19A1/NOGO A and 
SOD1/NOGOA ratios were found statistically significant 
in the sporadic ALS patients’ group (Fig. 3B). Selected 
cut-off values were set for COL19A1 gene (COL19A1 
gene >0.847), and for COL19A1/NOGO A ratio (ratio 
COL19A1/NOGO A >0.650), as well as for SOD1/NOGO 
A (ratio SOD1/NOGO A >0.960) to minimize false 
positive cases. These results showed that a parallel 
combination of COL19A1 and the ratio COL19A1/NOGO 
A improved performance, yielding a 78.7% sensitivity, 
while in the case of COL19A1 and the ratio SOD1/NOGO 
A, the sensitivity reached 70.7% (LR 6.214, CI 2.449-
15.771). Consequently, the relationship between 
COL19A1 levels and the ratios COL19A1/NOGO A and 
SOD1/NOGO A could be more indicative of muscle 
damage in the population of sporadic ALS patients. 
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Our next step was to investigate the relationship of 
these genes with the functional state in ALS patients. 
Spearman correlations between ALSFRS-r score at onset 
and COL19A1 levels (r= -0.345, P=0.001), MEF2C (r= 
0.228, P=0.038) and SNX10 (r= 0.494, P=0.000) gene 
levels were found significant, which suggested that high 
COL19A1 levels could be related to lower ALSFRS-r 
scores, indicating a high disability in the patient, while 
high MEF2C and SNX10 levels were more associated with 
a lower disability in the patient. Furthermore, COL19A1 
levels correlated negatively with the diagnostic delay (r= 
-0.210, P=0.040), reinforcing that COL19A1 levels could 
be involved in a faster progression of the disease. 
To investigate more in depth these correlations, 
binary logistic regression analysis was performed. We 
next explored the possible associations of these genes and 
the clinical variables measured in each patient that 
included ALSFRS-r at onset and at sampling, the 
diagnostic delay, age at onset, the revised El Escorial 
criteria, the onset site and the genetic diagnosis.  
COL19A1 levels were associated with an age at onset 
lower than 55 years (OR: 2.967, CI: 1.213-7.257, 
P=0.017), a defined El Escorial criteria (OR: 3.050, CI: 
1.266-7.350, P=0.013) and ALSFRS-r scores equal or 
lower than 40 (OR: 2.433, CI: 0.970-6.105, P=0.058), 
which is in accordance with the results observed in the 
muscle biopsy cohort. Therefore, high COL19A1 levels in 
blood could be also indicative of a worsening of the 
functional state and a high disability in the patient. 
Additionally, COL19A1 levels were also associated with 
a diagnostic delay lower than one year (OR: 0.953, CI: 
0.909-0.998, P=0.043). In contrast, SNX10 and NOGO A 
levels were more associated with ALSFRS-r scores at 
onset higher than 40 (SNX10, OR: 0.381, CI: 0.213-0.679, 
P=0.001; NOGO A, OR: 0.366, CI: 0.184-0.725, 
P=0.004), and an age at onset higher than 55 years (OR: 
0.333, CI: 0.167-0.665, P=0.002), suggesting that high 
SNX10 and NOGO A levels could be related to a lower 
disability in the patient. Interestingly, only in the case of 
MEF2C levels, a significant association was found 
between high levels of this gene and the bulbar and upper 
limb onset site of the disease (OR: 2.963, CI: 1.171-7.497, 
P=0.022), which could indicate an advanced muscle 
damage. In addition, COL19A1 levels were associated 
with the sporadic form of the disease (OR: 13.771, CI: 
2.520-75.255, P=0.002), while SNX10 levels were more 
associated with the familial form of the disease (OR: 
0.454, CI: 0.268-0.767, P=0.003).  
Our next step was to unravel which of these genes 
could influence the clinical features in the patients and 
therefore, multivariate logistic regressions were 
performed. SNX10 levels were found significantly 
associated with the familial ALS patients’ group (OR: 
0.489, CI: 0.268-0.892, P=0.020), with ALS patients with 
an age at onset higher than 55 years (OR: 0.351, CI: 
0.173-0.714, P=0.004), and with patients showing a 
possible, probable or suspected El Escorial criteria at 
onset (OR: 0.417, CI: 0.211-0.822, P=0.012). These 
findings suggested that SNX10 levels could be indicative 
of a late worsening in the functional state of the ALS 
patients. In contrast, COL19A1 levels were found 
significantly associated with sporadic ALS patients (OR: 
16.106, CI: 2.294-113.053, P=0.005), with patients that 
share an age at onset lower than 55 years (OR: 2.543, CI: 
1.007-6.422, P=0.048), and a defined El Escorial criteria 
(OR: 2.955, CI: 1.214-7.192, P=0.017), highlighting that 
COL19A1 levels could be more indicative of an earlier 
worsening in the functional state in the ALS patients. 
Finally and after analyzing the prognostic nature of 
the genes along the disease progression, Cox proportional 
hazards regression model suggested that COL19A1 gene 
levels above average (0.819) and a fast progression of the 
disease, based on high scores of the ALSFRS-r slope at 
onset ( 1 points/month) could favored a shorter lifespan 
in ALS patients (ALSFRS-r slope, HR: 5.798, CI: 3.405-
9.872, P<0.001; COL19A1 levels, HR: 2.291, CI: 1.435-
5.945, P=0.003). Notwithstanding, ALSFRS-r slope at 
sampling was also considering to be a potential predictor 
of disease progression, improving the accuracy of the 
prognostic prediction. Cox regression analysis, using 
leave-one-out cross validation, suggested that COL19A1 
gene levels above mean average (0.819) and high 
ALSFRS-r slope at sampling scores above mean average 
( 1 points/month) could promote a 20% reduction in the 
lifespan of ALS patients (COL19A1, HR: 2.114, CI: 
1.678-2.772, P=0.019, ALSFRS-r slope at sampling, HR: 
2.368, CI: 1.763-3.181, P<0.001).  
These findings reinforced the potential role of 
COL19A1 levels as strongest predictors of disease 
progression in this cross-sectional study, in which only 
one sample of blood was extracted from each participant 
and analyzed. The validation of these findings in serial 
blood samples obtained in a longitudinal study could 
finally unravel the prognostic nature of COL19A1 levels 
in ALS patients, and especially in sporadic cases to which 
COL19A1 was significantly associated. 
 
High COL19A1 levels enabled a more precise prognosis 
in patients that shared a high disability in the first 
symptomatic stages 
 
Blood serial samples obtained from the same patient can 
provide useful information about the variation of the 
expression profile of any molecular marker along the 
time. In addition, they can be easily monitored and studied 
in parallel with the clinical variables that each patient 
exhibit during the progression of the disease, especially 
the ASFRS-r scores and ALSFRS-r slope, in a 
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longitudinal study. Our hypothesis at this step was based 
on validating the prognostic nature of COL19A1 levels in 
blood serial samples along the disease progression. For 
this purpose, both time-dependent Cox regression 
analysis and linear mixed models were performed in the 
serial blood cohort. The linear mixed model analysis 
showed that ALS patients that exhibited high COL19A1 
levels from symptom onset also progressed faster during 
the follow-up period of 24 months from symptom onset 
(Estimate: -0,0093, CI: (-0,0181) - (-0,00039); P=0,042) 
(Fig. 4A). In addition, time-dependent Cox regression 
analysis, using leave-one-out cross validation, suggested 
that the lifespan of sporadic ALS patients showing 
COL19A1 levels above average (0.819) and a faster 
progression of the disease (ALSFRS-r slope at sampling 
scores  1 points/month) was reduced 17.9% (HR: 1.179, 
CI: 1.046-1.327, P=0.007), similarly to the result obtained 
in the blood cohort. Interestingly, ALS patients that 
showed COL19A1 levels below average from symptom 
onset (0.819) also showed a longer life expectancy and a 
light and progressive change in the ALSFRS-r scores at 
sampling in the follow-up period along disease 
progression than patients that showed COL19A1 levels 
above average (Fig. 4B). In accordance with the results 
obtained in the muscle biopsy and blood cohorts, these 
findings highlighted the prognostic nature of COL19A1 
levels in ALS patients that exhibited both COL19A1 
levels above average and ALSFRS-r slope at sampling 
scores  1 points/month in the serial blood cohort, 
suggesting that COL19A1 levels could be of valuable 
support in clinical practice when ALSFRS-r slope at 
sampling was also considered to monitor the ALS 
patients’ group. 
The prognostic nature of COL19A1 levels in the three 
cohorts under study is summarized in terms of the average 
values in COL19A1 levels and the corresponding 
ALSFRS-r slope at sampling scores (Table 6). 
 
 
 
Table 6. Prognostic nature of COL19A1 levels in the three cohorts under study. 
 
Group of ALS patients N COL19A1 levels ALSFRS-r slope Estimate HR (95% CI) P value 
       
Muscle cohort* 49 
above the mean 
average (1.06) 
≥ 1 points/month 0.203 1.225 (1.058 – 1.418) 0.007 
       
Blood cohort 59 
above the mean 
average (0.819) 
≥ 1 points/month 0.748 2.114 (1.134 – 3.941) 0.019 
       
Serial blood cohort 40 
above the mean 
average (0.819) 
≥ 1 points/month 0.164 1.179 (1.046 – 1.327) 0.007 
       
 
Cox regression analysis, using leave-one-out cross validation, suggested that in the group of ALS patients, both COL19A1 levels above the mean average 
at first evaluation and ALSFRS-r slope at sampling scores  1 points/month in each corresponding cohort of patients were associated with a shorter 
lifespan. N: number of enrolled ALS patients; ALSFRS-r slope at sampling; HR: hazard ratio; CI: confidence interval; * only in the case of the Muscle 
biopsy cohort, the COL19A1 levels corresponds to the protein levels. In the Blood cohort the finding was reproducible when using the average score for 
COL19A1 gene levels of 0.819, used in the Serial Blood cohort (P < 0.05, *; P < 0.001, **). 
 
DISCUSSION 
 
This study was designed and performed to identify more 
reliable prognostic biomarkers for ALS disease 
progression that could be in close connection with the 
clinical parameters for a better monitoring and 
stratification of the patients. The starting point in this 
study was the skeletal muscle tissue although we also 
explored blood tissue to identify and validate prognostic 
biomarkers in a non-invasive way. 
In muscle biopsy samples, COL19A1 gene and 
protein levels were significantly associated with the ALS 
patient group with respect to healthy controls and patients 
with ONP, suggesting that COL19A1 levels can be useful 
as molecular support for diagnosis in this tissue. In the 
ALS group, high COL19A1 gene levels were significantly 
associated with low ALSFRS-r scores, and high 
COL19A1 protein levels promoted a shorter lifespan in 
ALS patients that also showed high ALSFRS-r slope 
scores, and consequently, a faster disease progression. A 
similar situation was observed in blood samples. 
COL19A1 and MEF2C levels were associated with the 
ALS patient group with respect to healthy controls and 
patients with ONP. In the ALS group, high COL19A1 
levels in combination with age at onset, the revised El 
Escorial criteria, the diagnostic delay and ALSFRS-r 
scores were associated with a worse prognosis indicating 
a high disability in the patient. In contrast, high NOGO A 
and, especially SNX10 levels were related to a better 
prognosis in ALS patients. However, the prognostic 
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nature of these potential biomarkers in blood serial 
samples were only validated in the case of COL19A1 
levels since patients that exhibited high COL19A1 levels 
and a faster disease progression also showed a shorter 
lifespan. 
Collagen XIX accumulates in the extracellular matrix 
of restricted tissues, including neural tissue and it seems 
to modulate cell-matrix interactions and cell-cell 
communications [14,21]. Recently, the anti-tumor 
properties of COL19A1 in vitro have also been described, 
albeit it is involved in the differentiation of muscle cells, 
central nervous system development, and formation of the 
esophagus [22]. When muscle fibers are functionally 
denervated, as it happens in ALS disease, the subsynaptic 
membrane is able to restore its biochemical and structural 
organization [23]. The findings observed in muscle biopsy 
samples suggested that ALS patients that exhibited a 
faster disease progression they could also exhibited more 
severe muscle damage. Therefore, high levels of 
COL19A1 could act as a compensatory response when the 
disease progression is fast, which is in accordance with 
previous studies that suggested a close relationship 
between COL19A1 gene and ALS in muscle biopsies from 
ALS patients [24]. Furthermore, the remarkable 
difference in COL19A1 gene and protein levels observed 
in the ALS patients respect to the ONP group also 
suggested that COL19A1 could be involved in specific 
muscle defects that could enhance the desestabilization of 
motor neuron terminals, contributing especially to the 
neurodegenerative progression in ALS. Albeit the 
neuropathies included in this study also share in common 
with ALS intrinsic muscle defects, neuroinflammation, 
immune organ dysfunction, metabolic perturbations, 
defects in neuron excitability and selective motoneuron 
vulnerability and muscle denervation process, specific 
processes such as activation of regulatory myogenic 
factors [14] or the direct cross-talk between NMJ and 
axonal outgrowth could not be modulated in the same way 
as in ALS. Structural or functional alterations of skeletal 
muscle can hinder the transmission of chemical and 
electrical stimuli from the NMJ to the motor neurons, 
favoring the dying-back phenomena and therefore 
contributing to disease pathology [25]. Since COL19A1 
is a matrix protein involved in muscle physiology and 
differentiation [14], alterations in the COL19A1 gene or 
protein levels could point out tissue damage along disease 
progression in the neurodegenerative chain of ALS. 
In blood samples, high levels of COL19A1 could also 
represent a repressor stimulus to counteract the 
denervation processes along disease progression [9,23], 
and even an overstimulation of immune system in 
monocytes and dendritic cells by means of leukocyte-
associated immunoglobulin-like receptor 1 (LAIR-1) 
[26]. Recent studies have suggested a novel function of 
SNX10 in regulating macrophage polarization and 
function in mice under inflammatory conditions [27]. 
Considering that SNX10 has also been reported to be 
associated with a diminished production of systemic pro-
inflammatory cytokines [27], increasing SNX10 levels 
could favor macrophage polarization into M2 phenotype, 
exerting anti-inflammatory action after tissue injury in 
ALS patients, when the denervation process has started as 
increasing NOGO A levels suggested, which is in 
accordance with previous studies [28-32]. Remarkably, it 
has been reported that thirteen circulating markers of 
inflammation and of neuromuscular pathology changes 
were significantly altered in plasma from ALS patients, 
highlighting the role of inflammatory response and 
neuromuscular involvement in ALS [33,34]. Moreover, 
this is an interesting issue since only one recent study has 
identified blood-derived biomarker from peripheral 
lymphocytes in ALS patients. In this study, LILRA2, 
ITGB2 and CEBPD genes were identified as peripherally 
accessible candidate biomarkers in ALS [35]. These genes 
are related to the immune system but also they are in close 
connection with the crosstalk between microglia and 
motor neuron pathology. The clinical relevance of 
identifying blood-derived biomarkers from peripheral 
lymphocytes mainly relies on the fact that it is possible to 
monitor the impact of other tissues and systems that 
become damaged during disease progression, such as 
neuroinflammation, microglial activation or even muscle 
damage, in parallel with the clinical parameters that can 
be serially monitored in the patients, at the same time the 
expression profile of the biomarker candidate is tested in 
a non-invasive way. In this study, COL19A1 gene 
improved prognosis accuracy during disease progression 
not only in patients that were monitored at first evaluation 
in the blood cohort but also in serial samples and in 
patients that were monitored longitudinally at 6-monthly 
intervals during a follow-up period of 24 months, 
highlighting the prognostic role of this gene in the disease 
progression and in particular, in the sporadic form of the 
disease.  
The findings provided in this study revealed the 
potential use of COL19A1 to improve prognosis in the 
disease progression in a non-invasive way. The 
combination of high COL19A1 expression levels and a 
faster disease progression can promote a shorter life 
expectancy in ALS patients, and therefore COL19A1 
levels can be considered a reliable blood-derived 
biomarker in muscle biopsies and in blood to support the 
clinical practice and to be of help in future clinical trials, 
as well as a promising and novel therapeutic target in 
ALS. 
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